...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model
【24h】

Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model

机译:药代动力学在批判性患者对通过动态空心纤维感染模型评估的患者患者的重大影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Critically ill patients frequently have substantially altered pharmacokinetics compared to non-critically ill patients. We investigated the impact of pharma-cokinetic alterations on bacterial killing and resistance for commonly used meropenem dosing regimens. A Pseudomonas aeruginosa isolate (MICmeropenem 0.25 mg/liter) was studied in the hollow-fiber infection model (inoculum similar to 10(7.5) CFU/ml; 10 days). Pharmacokinetic profiles representing critically ill patients with augmented renal clearance (ARC), normal, or impaired renal function (creatinine clearances of 285, 120, or similar to 10 ml/min, respectively) were generated for three meropenem regimens (2, 1, and 0.5 g administered as 8-hourly 30-min infusions), plus 1 g given 12 hourly with impaired renal function. The time course of total and less-susceptible populations and MICs were determined. Mechanism-based modeling (MBM) was performed using S-ADAPT. All dosing regimens across all renal functions produced similar initial bacterial killing (<=similar to 2.5 log(10)). For all regimens subjected to ARC, regrowth occurred after 7 h. For normal and impaired renal function, bacterial killing continued until 23 to 47 h; regrowth then occurred with 0.5- and 1-g regimens with normal renal function (fT (>5 x MIC) = 56 and 69%, fC(min)/MIC < 2); the emergence of less-susceptible populations (>= 32-fold increases in MIC) accompanied all regrowth. Bacterial counts remained suppressed across 10 days with normal (2-g 8-hourly regimen) and impaired (all regimens) renal function (fT >5 x MIC >= 82%, fC(min)/MIC >= 2). The MBM successfully described bacterial killing and regrowth for all renal functions and regimens simultaneously. Optimized dosing regimens, including extended infusions and/or combinations, supported by MBM and Monte Carlo simulations, should be evaluated in the context of ARC to maximize bacterial killing and suppress resistance emergence.
机译:与非批判性患者相比,患者患者经常具有显着改变的药代动力学。我们调查了Pharma-Cokinetic改变对常用Meropenem给药方案的细菌杀伤和抗性的影响。在空心纤维感染模型中研究了假单胞菌铜绿假单胞菌(Micmeropenem 0.25 mg /升)(占状物,类似于10(7.5)CFU / ml; 10天)。代表具有增强肾脏间隙(ARC),正常或受损的肾功能(分别为285,120,或类似于10ml / min的肌酐间隙)的药代动力学曲线被为三个梅洛尼姆方案(2,1,和0.5g施用为8小时30分钟的输注),加上12小时给出1g,肾功能受损。确定了总和较弱的人群和麦克风的时间。使用S-Adapt进行基于机制的建模(MBM)。所有肾功能杂项的所有剂量方案都产生了类似的初始细菌杀伤(<=类似于2.5对数(10))。对于所有经过弧的方案,7小时后发生再生。对于正常和受损的肾功能,细菌丧失持续至23至47小时;然后用肾功能正常的0.5-和1-G方案发生再生(Ft(> 5×MIC)= 56和69%,Fc(min)/ Mic <2);含有较小易感群体的出现(> =麦克风的32倍)伴随着所有的再生。细菌计数仍然抑制在10天内,正常(2g 8-小时的方案)和损伤(全部方案)肾功能(FT> 5×MIC> = 82%,Fc(Min)/ MIC> = 2)。 MBM同时成功地描述了所有肾功能和方案的细菌杀死和再生。应在弧形的背景下评估优化的给药方案,包括由MBM和Monte Carlo模拟的扩展输注和/或组合,以最大化细菌杀伤和抑制抗抗血液的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号